Tugba Tunalı AKBAY, AYŞEN YARAT, ÖZLEM SAÇAN, REFİYE YANARDAĞ

The Effect of Glurenorm (Gliquidone) on aorta in STZ induced diabetic rats

Vasküler hastalıklar diyabetin yaygın komplikasyonlarından biridir. Diabette artan serbest radikal oluşumu ateroskleroz ve kardiyovasküler hastalıkların insidansını arttırır. Diyabetin tipinden bağımsız olarak tedavinin amacı, kan şekerini normal düzeyde tutarak komplikasyonları önlemektir. Glurenorm (gliquidone) sülfonilüre grubu antidiyabetiklerin bir üyesidir. Sülfonil üre oral antidiyabetikleri pankreasın beta hücrelerinden insulin çıkışını uyararak etki ederler Bu nedenle, çalışmanın amacı streptozotosin (STZ) ile diyabet oluşturulan sıçanların aortları üzerine glurenormun (gliquidone, 10 mg/kg) etkisini nonenzimatik glikasyon, lipid peroksidasyon ve indirgenmiş glutatyon açısından incelemektir. Diyabet ve kontrol gruplarındaki sıçanların hepsine deneyin sonu olan 42. güne kadar hergün ilaç verildi. 42. günde her sıçanın kan örnekleri ve aortları alındı. Kan glukozu o-toluidine metodu ile ölçüldü. Glurenorm diyabetik sıçanların kan şekerini düşürdü ve vücut ağırlıklarını arttırdı. Bununla birlikte, glurenorm diyabetik sıçanların aort proteinlerinin nonenzimatik glikasyonunu azaltmadı fakat lipid peroksidasyon seviyelerini azalttı. Glurenorm verilen diyabetik sıçanlarda lipid peroksidasyonu azalmasına rağmen glutatyon miktarı artmadı. Bu da oksidatif hasarın devam ettiğini göstermektedir. Glurenorm ayrıca aort proteinlerinin elektroforetik modelini de değiştirmedi. Bu sonuçlar glurenormun diyabetik sıçanların kan şekerini düşürmede etkili olduğu ancak aort dokusundaki nonenzimatik glikasyonu ve oksidatif hasarı azaltmadığını göstermektedir.

Anahtar Kelimeler:

deneysel diabetikler, Diabetes mellitus, diyabet, kalp damar hastalıkları, aorta, sıçan, lipit peroksidasyonu, hipoglisemik ajanlar, glutatyon

STZ ile Diyabet oluşturulan sıçanlarda glurenormun (gliquidone) aort üzerine etkisi

Vascular diseases are one of the common complications of diabetes mellitus. In diabetes, increased free radical formation raises the incidence of atherosclerosis and cardiovascular diseases. Regardless of the type of diabetes, the objective of the therapy is to achieve normoglycemia and to prevent or delay the complications. Glurenorm (gliquidone) is one of the members of sulphonylurea group oral antidiabetics. Sulphonylurea oral antidiabetics act via stimulating insulin release from β cells of the pancreas. Therefore, the aim of the study was to investigate the ef ect of glurenorm (gliquidone, 10 mg/kg) on the aorta of streptozotocin-induced diabetic rats in terms of nonenzymatic glycation, lipid peroxidation and reduced glutathione. Both diabetic and control group rats have taken the drug daily, until the end of the experiment, at day 42. Blood samples and aorta was taken from each rat at day 42. Blood glucose was measured by o-toluidine method. Glurenorm decreased the blood glucose and increased the body weights of diabetic rats. However, glurenorm did not decrease non-enzymatic glycation of aorta proteins in diabetic rats, but it decreased lipid peroxidation of aorta. Although the aorta lipid peroxidation level was decreased in glurenorm given diabetic rats, glutathione level did not increase. This may show that oxidative damage continues during the glurenorm treatment. Glurenorm also did not change the electrophoretic pattern of aorta proteins. The results indicate the usage of glurenorm is ef ective on decreasing of blood glucose but not on decreasing nonenzymatic glycation or oxidative damage in aorta samples of diabetic rats.

Keywords:

experimental diabetes, diabetes mellitus, diabetes, cardiovascular diseases, aorta, rats, lipid peroxidation, hypoglycaemic agents, glutathione,

PDF

___

1. Evcimen ND, King GL: The role of protein kinase C activation and the vascular complications of diabetes. Phamacol Res, 55, 498-510, 2007.
2. Machha A, Achike FI, Mustafa AM, Mustafa MR: Quercetin, a l avonoid antioxidant, modulates endothelium-derived nitric oxide bioavailability in diabetic rat aortas. Nitric Oxide, 16, 442-447, 2007.
3. Babu PVA, Sabith KE, Shyamaladevi CS: Therapeutic ef ect of green tea extract on oxidative stress in aorta and heart of streptozotocin diabetic rats. Chem-Biol Interact, 162, 114-120, 2006.
4. Von Nicolai H, Brickl R, Eschey H, Greischel A, Günther H, König E, Limmer J, Rupprecht E: Durations of action and pharmacokinetics of the oral antidiabetic drug gliquidone in patients with noninsulin-dependent (type 2) diabetes mellitus. Arzneim Forsch Drug Res, 47, 247-252, 1997.
5. Malaisse WJ: Gliquidone contributes to improvement of type 2 diabetes mellitus management: A review of pharmacokinetic and clinical trial data. Drugs R D, 7 (6): 331-337, 2006.
6. Relander A and Raiha CE: Dif erences between the enzymatic and toluidine methods of blood glucose determination. Scand J Clin Lab Invest, 15, 221-224, 1963.
7. Lowry OH, Rosebrough WI, Farr AL, Randal RJ: Protein measurement with the Folin phenol reagent. J Biol Chem, 193, 265-275, 1951.
8. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriofage T4. Nature, 227, 680-685, 1970.
9. Ledwozwy A, Michalak J, Stepien A, Kadziolka A: The relationship plasma triglycerides cholesterol, total lipids, and lipid peroxidation products during human atherosclerosis. Clin Chim Acta, 155, 275-284, 1986.
10. Beutler E: Glutathione in red blood cell metabolism: a manual of biochemical methods. pp. 112-114, Grune and Stratton, New York, 1975.
11. Parker KM, England JD, Casto JD, Hessel R and Goldstein PE: Improved colorimetric assay for glycosylated hemoglobin. Clin Chem, 27, 669-672, 1981.
12. Ergun G, Aktas S: ANOVA modellerinde kareler toplamı yöntemlerinin karşılaştırılması. Kafkas Univ Vet Fak Derg, 15 (3): 481-484, 2009.
13. Mendes M, Akkartal E: Comparison of ANOVA F and WELCH Tests with Their Respective Permutation Versions in Terms of Type I Error Rates and Test Power. Kafkas Univ Vet Fak Derg, 16 (5): 711-716, 2010.
14. Sun H, Zhong M, Miao Y, Ma X, Gong HP, Tan HW, Zhang Y, Zhang W: Impaired elastic properties of the aorta in fat-fed, streptozotocin- treated rats. Vascular remodeling in diabetic arteries. Cardiology, 114 (2): 107-113, 2009.
15. Zou MH, Cohen R, Ullrich V: Peroxynitrite and vascular endothelial dysfunction in diabetes mellitus. Endothelium, 11 (2): 89-97, 2004.
16. Yamasaki Y, Katakami N, Furukado S, Kitagawa K, Nagatsuka K, Kashiwagi A, Daida H, Kawamori R, Kaku K: Long-term ef ects of pioglitazone on carotid atherosclerosis in japanese patients with type 2 diabetes without a recent history of macrovascular morbidity. J Atheroscler Thromb, 2010 (in press).
17. Martens FM, van der Graaf Y, Dijk JM, Olijhoek JK, Visseren FL: Carotid arterial stif ness is marginally higher in the metabolic syndrome and markedly higher in type 2 diabetes mellitus in patients with manifestations of arterial disease. Atherosclerosis, 197 (2): 646-653, 2008.
18. Ugurlucan M, Erer D, Kalko Y, Gungor F, Haholu A, Basaran M, Banach M, Rysz J, Mikhailidis DP, Tireli E, Dayioglu E, Alpagut U: Aortic stif ness in diabetes mellitus association with glutamine and heat shock protein 70 expression: A pilot study based on an experimental rodent model. Expert Opin Ther Targets, 13 (3): 267-274, 2009.
19. Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M, Aoki T, Etoh T, Hashimoto T, Naruse M, Sano H, Utsumi H, Nawata H: High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes, 49, 1939-1945, 2000.
20. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, Channon KM: Mechanisms of increased vascular superoxide production in human diabetes mellitus: Role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation, 105, 1656-1662, 2002.
21. Sonta T, Inoguchi T, Tsubouchi H, Sekiguchi N, Kobayashi K, Matsumoto S, Utsumi H, Nawata H: Evidence for contribution of vascular NAD(P)H oxidase to increased oxidative stress in animal models of diabetes and obesity, Free Radic Biol Med, 37, 115-123, 2004.
22. Babior BM: NADPH oxidase. Curr Opin Immunol, 16 (1): 42-47, 2004.
23. Degtiareva II, Lodianaia EV., Opanasiuk ND, Palladina OL: The use of the hypoglycemic preparation gliquidone in patients with digestive organ diseases combined with diabetes mellitus. Lik-Sprava, 78, 84-87, 1995.
24. Dedov II, Demidova IIu, Pisklakov SV, Antokhin EA: Use of glurenorm in patients with non-insulin dependent diabetes mellitus and liver diseases. Probl Endocrinol Mosk 39, 6-8, 1993.
25. Balabolkin MI, Nedosugova LV: Glurenorm in the treatment of patients with noninsulin-dependent diabetes mellitus with diseases of the liver and bile ducts. Probl Endocrinol Mosk, 39, 16-18, 1993.
26. Sawada F, Inoguchi T, Tsubouchi H, Sasaki S, Fujii M, Maeda Y, Morinaga H, Nomura M, Kobayashi K, Takayanagi R: Dif erential ef ect of sulfonylureas on Production of reactive oxygen species and apoptosis in cultured pancreatic β-cell line, MIN6. Metabolism, 57 (8): 1038-1045, 2008.
27. Iwakura T, Fujimoto S, Kagimoto S, Inada A, Kubota A, Someya Y, Ihara Y, Yamada Y, Seino Y: Sustained enhancement of Ca2+ inl ux by glibenclamide induces apoptosis in RINm5F cells. Biochem Biophys Res Commun, 271, 422-428, 2000.
28. Yanardag R , Ozsoy-Sacan O, Orak H , Ozgey Y: Protective ef ects of glurenorm (gliquidone) treatment on the liver injury of experimental diabetes. Drug Chem Toxicol, 28 (4): 483-497, 2005.
29. Yarat A, Tunali T, Yanardag R, Gursoy (Ozcelik) F* , Sacan (Ozsoy) O, Emekli N, UstunerA, Ergenekon G: The ef ect of Glurenorm (gliquidone) on lenses and skin in experimental diabetes. Free Radic Biol Med, 31 (9): 1038-1042, 2001.
30. Prisant LM, Mehta P, Arora V, Gentry M, Waller JL: Relationship between glycosylated hemoglobin and arterial elasticity. Prev Cardiol, 9 (3): 160-165, 2006.
31. De Vriese AS, Van de Voorde J, Blom HJ, Vanhoutte PM, Verbeke M, Lameire NH: The impaired renal vasodilator response attributed to endothelium-derived hyperpolarizing factor in streptozotocin-induced diabetic rats is restored by 5-methyltetrahydrofolate. Diabetologia, 43 (9): 1116-1125, 2000.
32. Gurpinar T, Ekerbicer N, Uysal N, Barut T, Tarakci F, Tuglu MI: The histologic evaluation of atarvastatin and melatonin treatment on oxidative stress and apoptosis of diabetic rat pancreas. Kafkas Univ Vet Fak Derg, 16 (4): 547-552, 2010.